Imagen de Portada

Multicentre Retrospective and Prospective Analysis of Data on Emicizumab and Factor VIII Prophylaxis in Children With Severe Haemophilia A: Egypt‐Compare Study

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Tamer Hassan, Mohsen Elalfy, Mervat A. M. Youssef, Omar Elalfy, Elzahraa Elmasry, Gehan Lotfy Khalifa, Ahmad Darwish, Eslam E. Elhawary
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Haemophilia
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Dental Management of Persons With Haemophilia Receiving Emicizumab Prophylaxis
por: Branislav V. Bajkin, et al.
Publicado: (2026)

Low‐Dose Emicizumab Versus Low‐/Intermediate‐Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype
por: Nuchanun Kessakorn, et al.
Publicado: (2024)

Lifetime Cost‐Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis
por: Han Bao, et al.
Publicado: (2026)

Reduced‐Dose versus Standard‐Dose Emicizumab for Haemophilia A: A Retrospective Cohort Study
por: Huiling Yan, et al.
Publicado: (2025)

Coagulation Potential in Haemostatic Agents Concomitant With Low Concentration of Emicizumab Under Severe Haemophilia A State
por: Yuki Kawasaki, et al.
Publicado: (2025)

Milds Matter—Feasibility of Emicizumab Prophylaxis in Mild Hemophilia
por: Kyle Davis, et al.
Publicado: (2026)

HEAD‐US Score and Cartilage Biomarkers in Patients With Severe Haemophilia A Who Receive Low‐Dose Factor VIII Prophylaxis
por: Arpanan Pramualratthakarn, et al.
Publicado: (2026)

Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross‐Sectional, Single‐Centre Study
por: Ilenia Lorenza Calcaterra, et al.
Publicado: (2026)

Muscle Strength in Children and Adolescents With Haemophilia on Prophylaxis: An Age‐Adjusted Dynamometric Study
por: Dimitrios Syrengelas, et al.
Publicado: (2026)

TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab
por: Kagehiro Amano, et al.
Publicado: (2025)

Managing Acute Coronary Syndrome and Surgical Revascularization in a Patient With Severe Haemophilia A on Emicizumab: Lessons Learned From a Clinical Case
por: Paige Muir, et al.
Publicado: (2026)

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors
por: Midori Shima, et al.
Publicado: (2025)

Outcomes of Emicizumab Treatment for Haemophilia A Paediatric Patients: A Systematic Review With Meta‐Analysis
por: Konstantina Bolou, et al.
Publicado: (2025)

Haemophilia Prophylaxis in the Age of Innovation: Exploring Opportunities for Personalized Treatment
por: Yesim Dargaud, et al.
Publicado: (2025)

Adherence to Clotting Factor Prophylaxis in Adolescent and Adult Males With Haemophilia
por: Nathália Martins Beserra, et al.
Publicado: (2026)

Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients With Severe Haemophilia A: Results of an Interventional, Post‐Marketing Study
por: Pål André Holme, et al.
Publicado: (2025)

Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study
por: Luigi Piero Solimeno, et al.
Publicado: (2025)

Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis
por: Daniel Kraemmer, et al.
Publicado: (2025)

Differences Between Sweden and Greece in Joint Outcomes Assessed by Ultrasound in Adolescents With Severe Haemophilia on Prophylaxis: Data From the PedNet Registry
por: Aikaterini Michalopoulou, et al.
Publicado: (2025)

Impact of Family History of Haemophilia on Diagnosis, Management and Outcomes in Severe Haemophilia
por: Ana Mendoza, et al.
Publicado: (2025)

Extension Study With rVIII‐SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A
por: Johnny Mahlangu, et al.
Publicado: (2025)

Preclinical Atherosclerosis in Adolescents With Severe Haemophilia
por: Christian Saleh, et al.
Publicado: (2026)

Comprehensive Assessment of the Transition to Efanesoctocog Alfa Prophylaxis in a Paediatric Haemophilia A Cohort
por: Rubén Berrueco, et al.
Publicado: (2026)

Haemophilia Joint Health Score Ranges Across the Lifespan: Variation by Haemophilia Type and Severity
por: Beth Boulden Warren, et al.
Publicado: (2026)

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study
por: Midori Shima, et al.
Publicado: (2026)

UK Experience of Children With Inhibitors in Severe Haemophilia B: A Report by the UKHCDO Paediatric Working Party
por: Mary Mathias, et al.
Publicado: (2026)

A Global Cross‐Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A
por: Dagmar M. Hajducek, et al.
Publicado: (2025)

Efficacy and Safety of rVIII‐SingleChain in Surgical Prophylaxis
por: Faraizah Abdul Karim, et al.
Publicado: (2025)

Emicizumab and asparaginase, A first experience to share
por: Laurie Goubeau, et al.
Publicado: (2024)

Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments
por: Ting‐Wei Lyu, et al.
Publicado: (2026)

Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry
por: Kathelijn Fischer, et al.
Publicado: (2025)

Central Nervous System Bleeding in Children With Haemophilia in Limited Resource
por: Patcharee Komvilaisak, et al.
Publicado: (2026)

Developing a Two‐Sided Decision Box to Facilitate Shared Decision‐Making for Switching From Conventional to Pharmacokinetic‐Tailored Prophylaxis in Haemophilia
por: Arun Keepanasseril, et al.
Publicado: (2025)

Factor VIII Antibodies Demonstrate Type I or Type II Kinetics in Acquired Haemophilia A
por: Kirollos Kamel, et al.
Publicado: (2025)

Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A
por: Priyanka Raheja, et al.
Publicado: (2026)

Carotid Intima‐Media Thickness as a Marker of Subclinical Atherosclerosis in Adolescents With Severe Haemophilia
por: Alyson Trillo, et al.
Publicado: (2025)

Genetic Analysis and Reproductive Interventions for Two Rare Families Affected by Severe Haemophilia A
por: Shimin Yuan, et al.
Publicado: (2024)

Quality of Life and Treatment Satisfaction in People With Haemophilia on Fitusiran Prophylaxis: Evidence From a Subset of ATLAS‐OLE Trial Participants Mainly From India
por: Alok Srivastava, et al.
Publicado: (2025)

Emicizumab plasma levels after accelerated saturation in acquired haemophilia A
por: Tristan Kloeter, et al.
Publicado: (2024)

Haemophilia Care in India: A Multicentre Cross‐Sectional Analysis From the World Bleeding Disorders Registry Benchmarking Across Global Gross National Income Strata
por: Nita Radhakrishnan, et al.
Publicado: (2026)